Chronic Myelomonocytic Leukemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Orlando, Florida
  • +3 more
2022-03-31
Mar 31, 2022
S
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Recruiting
  • Acute Myeloid Leukemia
  • +14 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
2022-04-07
Apr 7, 2022
M
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-05
Apr 5, 2022
T
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
Recruiting
  • Acute Lymphoblastic Leukemia
  • +15 more
  • Hematopoietic Cell Transplantation
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
2022-04-01
Apr 1, 2022
F
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Recruiting
  • Juvenile Myelomonocytic Leukemia
  • +27 more
  • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
K
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Active, not recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Newcastle, New South Wales, Australia
  • +10 more
2022-03-29
Mar 29, 2022
N
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
Active, not recruiting
  • Acute Myeloid Leukemia
  • +9 more
  • Los Angeles, California
  • +5 more
2022-03-30
Mar 30, 2022
J
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Birmingham, Alabama
  • +24 more
2022-03-24
Mar 24, 2022
H
IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT
Recruiting
  • Leukemia, Myeloid, Acute
  • +5 more
  • Duesseldorf, NRW, Germany
  • +10 more
2022-03-21
Mar 21, 2022
P
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients - 2022
Completed
Has Results
  • Myelodysplastic Syndrome
  • +2 more
  • Birmingham, Alabama
  • +32 more
2022-03-14
Mar 14, 2022
R
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +36 more
  • Buffalo, New York
    Roswell Park Cancer Institute
2022-03-17
Mar 17, 2022
D
GVAX vs. Placebo for MDS/AML After Allo HSCT
Active, not recruiting
Has Results
  • Myelodysplastic Syndrome
  • +2 more
  • GVAX
  • +6 more
  • Boston, Massachusetts
  • +3 more
2022-02-23
Feb 23, 2022
F
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
M
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Active, not recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Baltimore, Maryland
  • +2 more
2022-02-25
Feb 25, 2022
F
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-07
Mar 7, 2022
M
Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia
Recruiting
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-04
Mar 4, 2022
R
Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
Not yet recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • (no location specified)
2022-02-17
Feb 17, 2022
N
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Active, not recruiting
Has Results
  • Anemia
  • +3 more
  • Epoetin Alfa
  • +2 more
  • Birmingham, Alabama
  • +512 more
2022-03-01
Mar 1, 2022
M
Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +25 more
  • Allogeneic Natural Killer Cell Line NK-92
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-01
Mar 1, 2022
C
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Active, not recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +125 more
  • tetanus-CMV fusion peptide vaccine
  • laboratory biomarker analysis
  • Duarte, California
    City of Hope Medical Center
2022-02-28
Feb 28, 2022
F
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Recruiting
  • Acute Lymphoblastic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-25
Feb 25, 2022
M
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Active, not recruiting
  • Acute Myeloid Leukemia With Multilineage Dysplasia
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
C
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Active, not recruiting
  • Adult Acute Lymphoblastic Leukemia in Remission
  • +6 more
  • Duarte, California
    City of Hope Medical Center
2022-02-17
Feb 17, 2022
P
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Active, not recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Salzburg, Austria
  • +17 more
2022-02-17
Feb 17, 2022
M
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Active, not recruiting
  • Chronic Myelomonocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-14
Feb 14, 2022